<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772367</url>
  </required_header>
  <id_info>
    <org_study_id>16-025</org_study_id>
    <nct_id>NCT02772367</nct_id>
  </id_info>
  <brief_title>Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients</brief_title>
  <official_title>Generation of Induced Pluripotent Stem Cell Derived Cardiomyocytes From Patients Exposed to Trastuzumab Therapy for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether cells from a biopsy taken from the&#xD;
      patient skin can be transformed into cardiomyocytes the changes in cardiomyocyte (heart&#xD;
      muscle cells) when grown in a special culture medium outside of the body. The structure and&#xD;
      function of these cells will then be studied to determine why some patients with breast&#xD;
      cancer who are treated with chemotherapy including anthracycline (e.g. Doxorubicin) and&#xD;
      anti-HER2 therapy (e.g. Herceptin) develop decreased heart function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>derive iPSs from skin fibroblasts</measure>
    <time_frame>1 day</time_frame>
    <description>described by Yamanaka et al with modification using the Millipore STEMCCA excisable polycystronic lentivirus reprogramming kit.2</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Patients</arm_group_label>
    <description>In study participants undergoing breast reconstruction surgery prior to breast radiation therapy, we will obtain skin tissue at the time of reconstruction surgery from the surgical specimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>skin punch biopsy</intervention_name>
    <arm_group_label>Breast Cancer Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      skin tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Potential research subjects will be identified by a member of the patient's treatment team,&#xD;
        the protocol investigator, or research team at Memorial Sloan Kettering Cancer Center&#xD;
        (MSKCC).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age greater than 18 years&#xD;
&#xD;
          -  Willing to participate in protocol procedures with signed informed consent&#xD;
&#xD;
          -  Assessment of LVEE via echocardiogram, cardiac MRI, or MUGA&#xD;
&#xD;
        Subjects in the cardiotoxicity group (TOX) must meet the following criteria:&#xD;
&#xD;
          -  History of HER2 positive breast cancer (stage I-IV)&#xD;
&#xD;
          -  Prior/current treatment with anthracycline based chemotherapy followed by anti-HER2&#xD;
             directed therapy or anti-HER2 directed therapy alone&#xD;
&#xD;
          -  Assessment of LVEF at baseline prior to initiation of anthracycline or anti-HER2&#xD;
             therapy and during anti-HER2 therapy via echocardiogram, cardiac MRI, or MUGA&#xD;
&#xD;
          -  Prior confirmed diagnosis of cardiotoxicity associated with anti-HER2 based therapy,&#xD;
             defined as a decrease in LVEF &gt; 10% from baseline to &lt; 53% with symptoms of heart&#xD;
             failure (NYHA class II-IV).&#xD;
&#xD;
        Subjects in the no cardiotoxicity group (NO-TOX) must meet the following criteria:&#xD;
&#xD;
          -  History of HER2 positive breast cancer (stage I-IV)&#xD;
&#xD;
          -  Completion of planned anthracycline and anti-HER2 therapy, or anti-HER2 therapy alone&#xD;
&#xD;
          -  No symptoms of heart failure (NYHA class II-IV) during and at the end of anthracycline&#xD;
             and anti-HER2 therapy&#xD;
&#xD;
          -  Assessment of LVEF at baseline prior to innitiation of anthracycline or anti-HER2&#xD;
             therapy and during anti-HER2 therapy via echocardiogram, cardiac MRI, or MUGA&#xD;
&#xD;
          -  Normal LVEF &gt;53% at each assessment during and at the end of trastuzumab therapy.&#xD;
&#xD;
          -  Maximum absolute decrease in LVEF &lt;5% from baseline during and at the end of&#xD;
             trastuzumab therapy.&#xD;
&#xD;
          -  LVEF assessment performed at baseline and at least two time points during trastuzumab&#xD;
             therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to give skin biopsies&#xD;
&#xD;
          -  Contraindications to punch biopsy including but not limited to bleeding diathesis, as&#xD;
             determined by the investigator.&#xD;
&#xD;
          -  Known pre-existing CV disease prior to initiation of breast cancer therapy as&#xD;
             determined by the investigator, including&#xD;
&#xD;
               -  Obstructive coronary artery disease (stenosis &gt;70%)&#xD;
&#xD;
               -  Arrhythmia - paroxysmal or persistent atrial arrhythmias, sustained ventricular&#xD;
                  tachycardia (&gt;30 seconds), ventricular fibrillation, or cardiac arrest&#xD;
&#xD;
               -  Cardiomyopathy (EF &lt;53%)&#xD;
&#xD;
               -  Heart failure (NYHA class II-IV)&#xD;
&#xD;
               -  Valvular heart disease with equal to or greater than moderate stenosis or&#xD;
                  regurgitation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angel Chan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angel Chan, MD, PhD</last_name>
    <phone>212-639-7217</phone>
    <email>chana5@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Richard Steingart, MD</last_name>
    <phone>212-639-8488</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Chan, MD, PhD</last_name>
      <phone>212-639-7217</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiotoxicity</keyword>
  <keyword>16-025</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

